454 filings
6-K
PPBT
Purple Biotech Ltd
25 Apr 24
Purple Biotech’s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
7:10am
EFFECT
PPBT
Purple Biotech Ltd
3 Apr 24
Notice of effectiveness
12:15am
POS AM
PPBT
Purple Biotech Ltd
28 Mar 24
Prospectus update (post-effective amendment)
4:01pm
6-K
PPBT
Purple Biotech Ltd
28 Mar 24
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
7:10am
6-K
PPBT
Purple Biotech Ltd
14 Mar 24
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
7:40am
6-K
9ag wnjd8
6 Mar 24
Report of Foreign Private Issuer
4:06pm
6-K
w8rygh
5 Mar 24
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
7:58am
6-K
m2upyjor2atn1
27 Feb 24
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
7:10am
SC 13G
c5hd6rx1dt
14 Feb 24
PURPLE BIOTECH / ARMISTICE CAPITAL ownership change
3:49pm
6-K
kxz7 5hwr1pi0y7a75n
13 Feb 24
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
7:10am
6-K
vf52zqztf
1 Feb 24
Report of Foreign Private Issuer
7:40am
6-K
4ipxh58km
26 Jan 24
Report of Foreign Private Issuer
4:15pm
6-K
cs2c5tb0eqj8jgsi
20 Dec 23
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
8:06am
6-K
r1mgnaxvryvfib62 x9
14 Dec 23
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
7:00am
6-K
xzdp5asgn qm
21 Nov 23
Report of Foreign Private Issuer
4:00pm
6-K
4k7u1vf0aw
21 Nov 23
Purple Biotech Reports Third Quarter 2023 Financial Results
7:00am
EFFECT
en0d9m9jza
15 Nov 23
Notice of effectiveness
12:15am
424B3
6h8whzbj8bgtxir rha
14 Nov 23
Prospectus supplement
4:13pm
F-1/A
vwk8cn5
13 Nov 23
Registration statement (foreign) (amended)
4:11pm